Clinical trials: Insufficient Metabolic Control
Diabetes Mellitus, Type 2
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
The purpose of this study is to assess the effectiveness of the co-administration of canagliflozin and metformin extended release (XR) compared with canagliflozin alone, and metformin XR alone in patients with type 2 diabetes…
- Trial name
- NCT01809327
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
- Where
- 129 sites in United States, Argentina and 11 more
- Volunteers
- 1,186 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy
Primary Objective: To investigate the efficacy(HbA1c) at 6 months after adding basal insulin therapy (insulin glargine) to dipeptidyl peptidase-IV (DPP-IV) and metformin plus or minus sulphonylurea Secondary Objectives: 1.
- Trial name
- TED (NCT02027753)
- Testing
- INSULIN GLARGINE, Metformin, DPP-4 inhibitor
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
- Trial name
- NCT01734785
- Testing
- Linagliptin, Empagliflozin + Linagliptin
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 607 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)
The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- NCT02831361
- Testing
- Gemigliptin, Metformin, Diet/exercise questionnaire
- Volunteers
- 290 people
- Sponsor
- LG Life Sciences
Type 2 Diabetes
Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)
A study to assess the safety and efficacy of sitagliptin 100mg compared to sitagliptin 200mg in patients with type 2 diabetes.
- Trial name
- NCT00541229
- Testing
- sitagliptin phosphate
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients in order to provide these data for approval for BI 10773 by regulatory authorities as an antidiabetic agent as add-on therapy to…
- Trial name
- NCT01210001
- Testing
- BI 10773
- Where
- 68 sites in United States, Canada and 5 more
- Volunteers
- 499 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03115112
- Testing
- Bexagliflozin, Sitagliptin
- Where
- 56 sites in United States, Czechia and 4 more
- Volunteers
- 386 people
- Sponsor
- Theracos
Diabetes Mellitus, Type 2
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00094757
- Testing
- Comparator: sitagliptin 100 mg, Comparator: sitagliptin 200 mg, Comparator: pioglitazone
- Volunteers
- 521 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Study of Multiple Doses of Saxagliptin (BMS-477118)
To evaluate the positive efficacy trend among doses of saxagliptin (BMS-477118) in subjects with Type 2 diabetes mellitus by assessing the change from baseline in HbA1c following 12 weeks of double-blind treatment.
- Trial name
- NCT00950599
- Testing
- Saxagliptin
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Glucose Intolerance
Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)
This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin (MK-0431/ONO-5435) used once daily (qd) in Japanese participants with impaired glucose tolerance who have inadequate glycemic control using…
- Trial name
- NCT01405911
- Testing
- Sitagliptin 25 mg, Sitagliptin 50 mg
- Volunteers
- 242 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
Long-term Study of SYR-472
To evaluate the safety and efficacy of long-term treatment with SYR-472 in diabetic patients.
- Trial name
- NCT01431807
- Testing
- SYR-472
- Where
- 41 sites in Japan
- Volunteers
- 680 people
- Sponsor
- Takeda
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in Asian patients with Type 2 Diabetes who are not well controlled on metformin alone.
- Trial name
- NCT01095666
- Testing
- Dapagliflozin, Metformin, Pioglitazone
- Where
- 33 sites in China, India and 1 more
- Volunteers
- 1,484 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
This study will assess the safety and tolerability of Ezetimibe (EZ) 10 mg/Atorvastatin (Atora) 10 mg and EZ 10mg/Atora 20 mg fixed-dose combination (FDC) in Japanese participants with hypercholesterolemia uncontrolled with…
- Trial name
- NCT02460159
- Testing
- EZ 10 mg/Atorva 20 mg FDC, EZ 10 mg/Atorva 10 mg FDC
- Volunteers
- 135 people
- Sponsor
- Organon and Co
Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
This Phase 3 study was designed to demonstrate the net benefit of sotagliflozin versus placebo in patients with Type 1 Diabetes (T1D).
- Trial name
- inTandem3 (NCT02531035)
- Testing
- Sotagliflozin
- Where
- 135 sites in United States, Argentina and 17 more
- Volunteers
- 1,405 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter, Phase 3 efficacy and safety study with 24-week and 52-week extension phases of simultaneous administration of exenatide once weekly (EQW) 2…
- Trial name
- NCT02229396
- Testing
- Exantide with Dapagliflozin, Exentide, Dapagliflozin
- Where
- 133 sites in United States, Hungary and 4 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
- Trial name
- NCT00621140
- Testing
- linagliptin
- Where
- 69 sites in Croatia, India and 9 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable insulin alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01590797
- Testing
- Sitagliptin, Insulin, Metformin
- Volunteers
- 467 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus
A multicenter, randomized, double-blind, placebo-controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202…
- Trial name
- NCT05814393
- Testing
- Treatment Period(JW0201), Extension Period(JW0201)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- JW Pharmaceutical
Diabetes Mellitus, Type 2
Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin
The purpose of this study is to evaluate the efficacy and safety of Janagliflozin compared to placebo, both in combination with Metformin, in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with…
- Trial name
- NCT03851432
- Testing
- Janagliflozin plus metformin
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Type 2 Diabetes
Evaluation of Dapagliflozin Taken Twice-daily
This study is being carried out to see if dapagliflozin - administered in a daily dose of 2.5 mg given twice a day or 5 mg twice a day or 10mg once daily - in addition to metformin, is beneficial in diabetes treatment, and if so…
- Trial name
- NCT01217892
- Testing
- dapagliflozin, metformin
- Where
- 55 sites in Germany, Hungary and 5 more
- Volunteers
- 400 people
- Sponsor
- AstraZeneca